IMMEDIATE HAART REDUCES DEATH AND AIDS PROGRESSION OVER 48 WEEKS IN PATIENTS WITH ACUTE OIS

HIV Treat Bull - 2008 May-June;9(5/6):11

Simon Collins, HIV i-Base

Andrew Zalopa from Stanford University and colleagues presented results from ACTG A5164 Phase 4 study which randomised 282 patients to either immediate or deferred use of ARVs in the context of an acute OI diagnosis for which treatment is available (TB was excluded).

Optimal timing of HAART in this context is currently guided more by expert opinion than data from randomised studies, and is difficult due to the advanced illness of study participants.

Patients needed to be treatment naïve, not to have used ARVs in the previous 8 weeks or not to have used treatment for more than one month if used in the past. Deferred treatment was defined as after OI treatment (at least 4 weeks after randomisation). Randomisation was stratified by OI and CD4 (above and below 50 cells/mm³). Patients with tuberculosis were excluded. The primary week 48 endpoint was an ordered categorical variable of three outcomes: death/AIDS progression; no progression, HIV viral load <50copies/mL; or no progression, viral load <50 copies/mL.

Baseline characteristics included median (IQR) CD4 and viral load counts of 29 (10-55) cells/mm³ and 5.07 (4.71-5.63) log copies/mL. Over 90% were treatment naïve. Median age was 38 years; 85% men/15% women; 37% black, 36% Hispanic, and 23% white.

OIs included PCP (63%), cryptococcal meningitis (13%), pneumonia (10%), other OI including cyrptosporidiosis, toxoplasmosis, CMV and MAC (25%). One third of patients were diagnosed with more than one OI within 30 days.

Immediate and deferred arms started ART a median (IQR) of 12 (9-13) and 45 (41-55) days, respectively, after treatment for the opportunistic infection had started. 10% of the deferred treatment arm did not start HAART. Choice of ARVs was open with 89% and 85% patients in the immediate and deferred arms respectively, starting with a boosted-PI based regimen. 13% patients were lost to follow-up (18 in each arm). Although there was no significant difference in the composite primary endpoint with both arms achieved similar CD4 and viral load by week 24, the immediate arm had significant clinical benefits.

Immediate HAART led to fewer deaths/AIDS progressions (n=20 vs 34, p=0.035), longer time to death/AIDS progression (stratified HR = 0.53, 99% CI 0.25-1.09, p=0.02), and shorter time to achieving an increase in CD4 counts to >50 and >100 (median 8.1 vs 3.9 weeks and 11.8 vs 4.2 weeks, both p<0.001), respectively.

There was a trend of earlier ART changes in the immediate arm (p=0.15), but no significant differences in grade 3 or 4 adverse events, adherence, hospitalizations, or immune reconstitution inflammatory syndrome (8 immediate vs 12 deferred).

The clinical benefits from immediate treatment were driven by the more rapid increase in CD4 count, which decreased the period of vulnerability to new AIDS-related infections and death.

Comment

It is important that the question of HAART timing has been answered in a randomised study. The acknowledgement of patients for participating in this study, many of whom were already ‘disenfranchised from the US healthcare system’, was particularly important.

Ref: Zolopa A, Andersen J, Komarow L et al. Immediate vs Deferred ART in the Setting of Acute AIDS-related Opportunistic Infection: Final Results of a Randomized Strategy Trial, ACTG A5164. Conf Retroviruses Opportunistic Infect. 2008 Feb 3-6;15: Oral abstract 142.

This presentation is also available as a webcast (Wed 6th Feb).

2008-05-10
IB080905-08

©2008. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2008. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 2008. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.